What is a stock summary page? Click here for an overview.
Business Description
Microbix Biosystems Inc
NAICS : 325414
SIC : 3741
ISIN : CA59501P1045
Description
Microbix Biosystems Inc develops biological products and technologies. There are two operating segments: The development, manufacturing, and sale of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and; Development and commercialization of novel and proprietary products or technologies such as Kinlytic. Geographically, it derives a majority of revenue from North America and also operates in Europe and other foreign countries.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.03 | |||||
| Equity-to-Asset | 0.74 | |||||
| Debt-to-Equity | 0.22 | |||||
| Debt-to-EBITDA | 1.38 | |||||
| Interest Coverage | 2.49 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 3.7 | |||||
| Beneish M-Score | -2.52 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 12.2 | |||||
| 3-Year EBITDA Growth Rate | 4 | |||||
| 3-Year FCF Growth Rate | 44.2 | |||||
| 3-Year Book Growth Rate | 12.4 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 38.53 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 22.91 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 46.54 | |||||
| 9-Day RSI | 48.76 | |||||
| 14-Day RSI | 47.37 | |||||
| 3-1 Month Momentum % | 7.32 | |||||
| 6-1 Month Momentum % | 33.33 | |||||
| 12-1 Month Momentum % | 20.55 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.62 | |||||
| Quick Ratio | 4.8 | |||||
| Cash Ratio | 3.36 | |||||
| Days Inventory | 231.76 | |||||
| Days Sales Outstanding | 67.54 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -2.4 | |||||
| Shareholder Yield % | 2.6 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 56.11 | |||||
| Operating Margin % | 10.01 | |||||
| Net Margin % | 8.35 | |||||
| FCF Margin % | 7.5 | |||||
| ROE % | 6.85 | |||||
| ROA % | 5.06 | |||||
| ROIC % | 10.08 | |||||
| 3-Year ROIIC % | -20.14 | |||||
| ROC (Joel Greenblatt) % | 17.07 | |||||
| ROCE % | 8.69 | |||||
| Years of Profitability over Past 10-Year | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 29.29 | |||||
| Forward PE Ratio | 13.67 | |||||
| PE Ratio without NRI | 29.29 | |||||
| Price-to-Owner-Earnings | 37.27 | |||||
| PS Ratio | 2.44 | |||||
| PB Ratio | 1.91 | |||||
| Price-to-Tangible-Book | 2.28 | |||||
| Price-to-Free-Cash-Flow | 34.17 | |||||
| Price-to-Operating-Cash-Flow | 14.64 | |||||
| EV-to-EBIT | 17.17 | |||||
| EV-to-EBITDA | 11.04 | |||||
| EV-to-Revenue | 2.23 | |||||
| EV-to-Forward-Revenue | 1.91 | |||||
| EV-to-FCF | 29.78 | |||||
| Price-to-GF-Value | 0.79 | |||||
| Price-to-Projected-FCF | 2.16 | |||||
| Price-to-Median-PS-Value | 0.93 | |||||
| Price-to-Graham-Number | 1.71 | |||||
| Price-to-Net-Current-Asset-Value | 3.73 | |||||
| Price-to-Net-Cash | 20.5 | |||||
| Earnings Yield (Greenblatt) % | 5.82 | |||||
| FCF Yield % | 2.98 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Microbix Biosystems Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil C$) | 23.03 | ||
| EPS (TTM) (C$) | 0.014 | ||
| Beta | 0.45 | ||
| 3-Year Sharpe Ratio | -0.06 | ||
| 3-Year Sortino Ratio | -0.11 | ||
| Volatility % | 50.2 | ||
| 14-Day RSI | 47.37 | ||
| 14-Day ATR (C$) | 0.022564 | ||
| 20-Day SMA (C$) | 0.397 | ||
| 12-1 Month Momentum % | 20.55 | ||
| 52-Week Range (C$) | 0.29 - 0.55 | ||
| Shares Outstanding (Mil) | 141.64 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Microbix Biosystems Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Microbix Biosystems Inc Stock Events
| Event | Date | Price (C$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Microbix Biosystems Inc Frequently Asked Questions
What is Microbix Biosystems Inc(TSX:MBX)'s stock price today?
The current price of TSX:MBX is C$0.41. The 52 week high of TSX:MBX is C$0.55 and 52 week low is C$0.29.
When is next earnings date of Microbix Biosystems Inc(TSX:MBX)?
The next earnings date of Microbix Biosystems Inc(TSX:MBX) is .
Does Microbix Biosystems Inc(TSX:MBX) pay dividends? If so, how much?
Microbix Biosystems Inc(TSX:MBX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers